Fate Therapeutics (NASDAQ:FATE – Get Free Report) and HilleVax (NASDAQ:HLVX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, risk and valuation.
Profitability
This table compares Fate Therapeutics and HilleVax’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fate Therapeutics | -1,325.43% | -45.88% | -33.95% |
| HilleVax | N/A | -67.27% | -51.99% |
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Fate Therapeutics and HilleVax, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fate Therapeutics | 0 | 7 | 3 | 0 | 2.30 |
| HilleVax | 0 | 6 | 0 | 0 | 2.00 |
Risk & Volatility
Fate Therapeutics has a beta of 1.95, meaning that its share price is 95% more volatile than the S&P 500. Comparatively, HilleVax has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500.
Institutional & Insider Ownership
97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 86.4% of HilleVax shares are held by institutional investors. 5.0% of Fate Therapeutics shares are held by insiders. Comparatively, 71.1% of HilleVax shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Fate Therapeutics and HilleVax”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fate Therapeutics | $13.45 million | 14.27 | -$160.93 million | ($1.65) | -1.02 |
| HilleVax | N/A | N/A | -$123.57 million | ($3.10) | -0.60 |
HilleVax has lower revenue, but higher earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than HilleVax, indicating that it is currently the more affordable of the two stocks.
Summary
Fate Therapeutics beats HilleVax on 9 of the 13 factors compared between the two stocks.
About Fate Therapeutics
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
About HilleVax
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
